Dare Bioscience, Inc. (NASDAQ:DARE) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET
Company Participants
Sabrina Johnson - President, CEO, Secretary & Director
John A. Fair - Chief Strategy Officer
Lisa Walters-Hoffert - CFO
Conference Call Participants
Operator
Good . My name is Joanne, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dare Bioscience, Inc. Q2 2022 Conference Call. [Operator Instructions]. Ms. Johnson, you may begin your conference.
Sabrina Johnson
Wonderful. Thank you. Good afternoon, and welcome to our Second Quarter 2022 Financial Results and Business Update Call for Dare Bioscience. Our plan today is to review our second quarter results, discuss development since our last call in May and use the time to review our business strategy and highlight our objectives and milestones anticipated for the rest of 2022.
Before we begin, I would like to remind you that today's discussion will include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements.
Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our annual report on Form 10-K for the year ended December 31, 2021, which was filed on March 31, 2022, and our quarterly report on Form 10-Q for the quarter ended June 30, 2022, which was filed today. I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, August 9, 2022. Dare undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.
As you know, Dare is solely and squarely focused in women's health. It is our belief that prioritizing women's health is not only good for the many women lacking effective or convenient therapeutic choices, but also for a broad set of stakeholders, including their families and partners and, of course, our shareholders. We work to accelerate innovative differentiated product options in contraception, vaginal health, sexual health and fertility, that expand treatment options were not exist, but enhanced outcomes where current standard of care has meaningful shortcomings and that improve ease of use for women where a more compelling form factor can drive adoption. Why? Because these are compelling markets impacting millions of women, and we have seen that innovation in these areas has led to commercially successful brands.